Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
109.81
+4.04 (3.82%)
At close: Jun 11, 2026, 4:00 PM EDT
109.79
-0.02 (-0.02%)
After-hours: Jun 11, 2026, 4:00 PM EDT

Protagonist Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $118.69. The average 1-year stock price forecast is 8.09% higher than the current stock price, while the lowest is $100 (-8.93%) and the highest is $137 (+24.76%).

Price Target: $118.69 (+8.09%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$100$118.69$118$137
Change-8.93%+8.09%+7.46%+24.76%

Analyst Ratings

The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy888899
Buy333333
Hold111111
Sell000000
Strong Sell000000
Total121212121313

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Buy
Maintains
$106$113
BuyMaintains$106$113+2.91%May 14, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$117
BuyReiterates$117+6.55%May 11, 2026
Citi
Citi
Buy
Maintains
$125$130
BuyMaintains$125$130+18.39%May 10, 2026
Citizens JMP
Citizens JMP
Buy
Maintains
$120$137
BuyMaintains$120$137+24.76%May 7, 2026
Goldman Sachs
Goldman Sachs
Hold
Maintains
$97$110
HoldMaintains$97$110+0.17%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
509.21M
from 46.02M
Increased by 1,006.59%
Revenue Next Year
159.78M
from 509.21M
Decreased by -68.62%
EPS This Year
4.17
from -2.05
EPS Next Year
-0.68
from 4.17
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
27.36M26.58M60.00M434.43M46.02M509.21M
Revenue Growth
-4.44%-2.84%125.73%624.06%-89.41%1,006.59%
Gross Profit
27.36M26.58M60.00M434.43M46.02M473.57M
Gross Margin
100.00%100.00%100.00%100.00%100.00%93.00%
Operating Income
-125.85M-131.37M-93.65M252.84M-158.13M262.85M
Net Income
-125.55M-127.39M-78.96M275.19M-130.15M258.16M
EPS
-----2.054.17
Forward PE
----59.7626.31
Free Cash Flow
-61.59M-60.37M-43.31M65.11M105.62M311.00M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High586.6M
Avg509.2M
Low129.0M

Revenue Growth

Revenue Growth202620272028
High
1,174.8%
Avg
1,006.6%
Low
180.3%

EPS Forecast

EPS202620272028
High5.88
Avg4.17
Low-1.00

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-